Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study. AbbVie has initiated a study titled ‘A Prospective, ...

AbbVie is conducting a study titled ‘SUNRISE-UC’ to evaluate the effectiveness and safety of Risankizumab in patients with moderate to severe ulcerative colitis. This real-world study aims to assess ...

In this head-to-head clinical trial of risankizumab and ustekinumab involving patients with moderate-to-severe Crohn’s disease who had had unacceptable side effects with anti-TNF therapy or an ...

Risankizumab was shown to produce rapid and durable clearing of skin lesions in a phase 1 trial involving patients with moderate-to-severe psoriasis. 15 This 48-week phase 2 trial of risankizumab ...

Risankizumab outperforms ustekinumab in treating moderate-to-severe Crohn’s disease Download PDF Copy By Dr. Sanchari Sinha Dutta, Ph.D. Reviewed by Benedette Cuffari, M.Sc. Aug 23 2024 ...

Phase 3b results show risankizumab is superior for endoscopic remission and clinical remission at week 48 compared with ustekinumab, a "once in a career" result, study authors say.

At week 16, 55.9% of the risankizumab group and 5.1% of the apremilast group achieved PASI 90. 75.4% of risankizumab-treated patients vs. 18.4% of apremilast-treated patients achieved sPGA 0/1 by ...

Risankizumab is an interleukin (IL)-23 p19 inhibitor that was approved for the treatment of adults with moderately to severely active Crohn's disease in June 2022, while ustekinumab is an IL-12/23 ...

Risankizumab, an interleukin-23 (IL-23) inhibitor, is currently marketed under the trade name Skyrizi and is approved for the treatment of active psoriatic arthritis, moderately to severely active ...

In the risankizumab arm, 84.7% of patients achieved PASI 75 at week 16 vs 18.8% of patients in the apremilast arm (secondary endpoint; P <.001).

Risankizumab is approved in the United States for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. It is a humanized ...

Risankizumab appeared to worsen severe asthma symptoms compared with placebo, according to results of a randomized phase 2a study published in The New England Journal of Medicine. Risankizumab ...